Aeterna Zentaris, Inc. (AEZS) Obtains FDA Investigational New Drug Approval for Leading Bladder Cancer Indication
Aeterna Zentaris Inc. is an innovative developer of oncology and endocrine therapies like Cetrotide®, which was the very first luteinizing hormone-releasing hormone (LHRH) to obtain approval for in vitro fertilization, announced FDA approval of an Investigational New Drug (IND) application for AEZS-108 bladder cancer treatment (a conjugate compound targeting doxorubicin in LHRH-receptor-positive urothelial cells). Phase 2 clinical trials on 64 male/female patients in advanced stages of the disease are slated for the latter half of this year, and will be conducted by Assistant Professor of Medicine, Gustavo Fernandez, M.D., at the Sylvester Comprehensive Cancer Center at the University of Miami’s…